Skip to search formSkip to main contentSkip to account menu

Benserazide

Known as: DL-Seryltrihydroxybenzylhydrazine, DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide, Benserazide [Chemical/Ingredient] 
An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism… 
National Institutes of Health

Related topics

Related topics

14 relations

Broader (3)

Antiparkinson AgentsDopaminergic AgentsEnzyme Inhibitors

Narrower (4)

Benserazide / LevodopaBenserazide hydrochlorideMadoparRo 4-4602
In Bloodagonistsanalogs & derivativesantagonists & inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A New Approach to Enhance Bioavailability : Dosage Forms with Extended Residence Time in the Stomach
In recent years there has been an increase in studies aiming to enhance bioavailability by extending the residence time of active… 
1989
1989
The putatively antipsychotic agent amperozide produces behavioural stimulation in the rat
SummaryAmperozide (FG 5606; N-ethyl-4-[4′,4′-bis(p-fluorophenyl) butyl]-1-piperazinecarboximide) is a new putatively… 
1987
1987
Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
In a open study in 13 patients with Parkinson's disease with 'on-off' fluctuations, all (n = 3) or part (n = 10) of the usual… 
1987
1987
Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo
SummaryBudipine, a new 4,4-diphenylpiperidine derivative, and placebo were administered three times daily to 31 patients with… 
1987
1987
Effects of 5-hydroxytryptamine, dopamine, and aromatic L-amino acids on growth hormone (GH)-releasing factor-stimulated GH release in rat anterior pituitaries.
The importance of monoaminergic mechanisms for the regulation of GH-releasing factor (GRF)-stimulated GH secretion was studied in… 
1979
1979
Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism.
A clinical evaluation was carried out in 20 elderly patients with parkinsonism to assess the effectiveness and acceptability of… 
1979
1979
Lack of counteracting effect of liposomes on benserazide-induced hyperprolactinemia.
Benserazide induces an increase of serum prolactin in man, possibly as the result of an impairment of the dopamine effect on the… 
1979
1979
Lupus-like autoimmune syndrome after levodopa and benserazide.
introduction of 100 U/ml insulin is difficulty in measuring small doses, but this does not seem to be a problem with modern… 
1978
1978
Inhibition of kynurenine hydrolase by benserazide, carbidopa and other aromatic hydrazine derivatives: evidence for sub-clinical iatrogenic niacin deficiency [proceedings].
It has been shown previously that kynurenine hydrolase (L-kynurenine hydrolase, EC 3.7.1.3) is inhibited by the hydrazide… 
1977
1977
["Beginning and end of dose" dyskinesias caused by L-DOPA].
The four cases of dyskinesia at the "beginning and end of dose" caused by L-Dopa presented in this series were characterized by…